Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Genistein, a soy isoflavone, exhibits anti-tumor properties across various malignancies.
• Cervical cancer remains a significant global health concern, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the anti-proliferative effects of genistein on cervical cancer cell lines (HeLa and CaSki).
• To elucidate the underlying molecular mechanisms, including key signaling pathways involved in genistein's action.

Main Methods:

• Cell viability assays were performed on HeLa and CaSki cells treated with varying concentrations of genistein.
• Western blotting was employed to analyze the phosphorylation status of AKT, ERK1/2, p38 MAPK, and JNK.
• Specific pathway inhibitors were used to determine the role of each signaling molecule in genistein's effects.

Main Results:

• Genistein significantly suppressed the growth of both HeLa and CaSki cells.
• Genistein reduced AKT and ERK1/2 phosphorylation while increasing p38 MAPK and JNK phosphorylation.
• Inhibition of ERK1/2 enhanced genistein's anti-proliferative effect, whereas p38 MAPK inhibition rescued cells from genistein-induced growth inhibition.
• AKT inhibition partially rescued CaSki cells but not HeLa cells, and JNK inhibition had minimal impact.

Conclusions:

• Genistein inhibits cervical cancer cell growth through a mechanism involving the suppression of ERK1/2 signaling and activation of the p38 MAPK pathway.
• These findings highlight genistein's potential as a therapeutic agent for cervical cancer, warranting further investigation into its precise molecular targets.